The tyrosine kinase inhibitor ponatinib is now listed on the PBS for treatment of patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). Ponatinib has an Authority Required listing from 1 September for management of patients with Ph+ ALL who have failed or are intolerant to dasatinib but do not have the ...
Ponatinib gets additional PBS indication for ALL
By Michael Woodhead
5 Sep 2018